Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
PR Newswire•11/11/2026•07:00 ET
0
Key Highlights
- ➤Genprex to present diabetes gene therapy strategy at Nov. 17-18 virtual symposium
- ➤AAV approach delivers Pdx1 and MafA genes to reprogram pancreatic cells
- ➤Non-viral lipid-based approach may offer treatment flexibility, including repeat dosing
- ➤Both diabetes gene therapy approaches remain in preclinical development
- ➤Genprex aims to advance diabetes program toward IND-enabling studies
Expert Statements
Ryan Confer, President and Chief Executive Officer at Genprex
“Advancing gene therapies requires not only innovative science, but also a disciplined approach to delivery, manufacturing and product development”
Ryan Confer, President and Chief Executive Officer at Genprex
“Our work evaluating both AAV-based and lipid-based approaches reflect our commitment to addressing important development challenges as we advance our diabetes gene therapy program. We are pleased to have Dr. Lachance share insights from this work with the broader cell and gene therapy community.”
Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium PR Newswire
Genprex Senior Director of Quality Control & Product Development to Present Insights from Parallel AAV and Lipid-Based Development Programs
Get started
Create a free account to read the full story.